1. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Issue 10378 (4th March 2023) Authors: Kimball, Alexa B; Jemec, Gregor B E; Alavi, Afsaneh; Reguiai, Ziad; Gottlieb, Alice B; Bechara, Falk G; Paul, Carle; Giamarellos Bourboulis, Evangelos J; Villani, Axel P; Schwinn, Andreas; Ruëff, Franziska; Pillay Ramaya, Larisha; Reich, Adam; Lobo, Ines; Sinclair, Rodney; Passeron, Thierry; Mart... Journal: Lancet Issue: Volume 401:Issue 10378(2023) Page Start: 747 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗